11/18/2024
4:26 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/18/2024
4:27 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/18/2024
5:50 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
3:53 PM | GREAT POINT PARTNERS LLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
11/14/2024
2:24 PM | JANUS HENDERSON GROUP PLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
11/14/2024
2:05 PM | Cormorant Asset Management, LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
11/14/2024
5:22 AM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SC 13G | |
|
11/04/2024
6:33 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/09/2024
3:15 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/09/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/07/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/08/2024
3:36 PM | BlackRock Inc. (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G | |
06/21/2024
7:32 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/18/2024
1:11 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
1:35 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
1:35 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:36 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Noonberg Sarah B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:36 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:37 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
PALEKAR ROHAN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
1:37 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Woods Robert Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/10/2024
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2024
5:20 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form DEF 14A | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form ARS | |
04/26/2024
1:34 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form DEFA14A | |
04/22/2024
3:44 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/02/2024
2:43 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/14/2024
7:51 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/14/2024
7:53 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/14/2024
7:54 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
3:29 PM | Babler Martin (Reporting)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
5:20 PM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
Smith Sean Michael (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
6:30 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2024
3:16 PM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/14/2024
5:05 PM | EcoR1 Capital, LLC (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G | |
02/14/2024
8:19 AM | Lynx1 Capital Management LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13G/A | |
02/09/2024
3:35 PM | Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
SIMPSON TODD E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/18/2024
5:56 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Noonberg Sarah B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:58 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
PALEKAR ROHAN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
6:01 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Woods Robert Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Trump said you could learn something from this man (Ad) Early Warning: A Deep Crack Is Forming In The US Economy
Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.  Here’s everything you need to know. |
01/18/2024
5:45 PM | Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
01/18/2024
5:48 PM | Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:51 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:53 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
6:11 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/26/2023
5:04 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:05 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:10 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:10 PM | Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
Woods Robert Keith (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:12 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:16 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/20/2023
5:43 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neurogene Inc. (Issuer)
Neoleukin Therapeutics (Issuer)
Neurogene Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2023
4:24 PM | BAKER BROS. ADVISORS LP (Filed by)
Neurogene Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neurogene Inc. (Subject)
| Form SC 13D/A | |
12/19/2023
6:31 AM | Neurogene Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neurogene Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
3:21 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
3:24 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form 425 | |
12/04/2023
4:10 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics (Filer)
Neoleukin Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/04/2023
4:14 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics (Subject)
Neoleukin Therapeutics, Inc. (Subject)
| Form 425 | |
